ClinicalTrials.gg
RecruitingNCT06257355Updated Apr 7, 2026

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

A Phase 1 interventional study of CSB-001 Ophthalmic Solution 0.1% in Corneal Scar, sponsored by Claris Biotherapeutics, Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Claris Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Corneal Injuries with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Corneal Injuries · United States.

Planned enrollment
7th of 12
20 · median 22
Started
2024
with 1 other
Phase 1
2 of 15
1 open now
Registered
13th of 15
by date
Lead sponsor
1 of 15
Claris Biotherapeutics, Inc.

Among the 15 studies in Corneal Injuries with a site in United States, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 13th registered.

Corneal Injuries

38 studies on the registry are indexed under Corneal Injuries; 8 are open to participants now.

Browse Corneal Injuries studies →

Open to participants now

4 of the 15 studies in Corneal Injuries with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Corneal Injuries studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Corneal Injuries with a site in United States, or all of them as a file.
02

Study summary

This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.

03

Conditions studied

  • Corneal Scar

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Centrally or paracentrally located scar approximately ≤5 mm and ≥2 mm in the greatest diameter and with a portion of the scar within approximately 3.5 mm of the optical center of the cornea assessed at Screening and confirmed at Baseline, and subject reports ability to detect any effect of scar on any element of vision.
  • Eye with a recent corneal insult approximately ≤30 days and ≥7 days from the Screening Visit.
  • Corneal insult includes but is not limited to mechanical / chemical / thermal injury, bacterial keratitis, PRK, and contact lens related ulcer.
  • Eye with observed rate of epithelialization that in the investigator's opinion does not demonstrate clinical characteristics of a slow healing (persistent defect) cornea.
  • Subjects must have the ability and willingness to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Corneal scar that encompasses more than approximately 50% of the depth of the remaining stroma as guided by ASOCT image at the Screening Visit.
  • Maximum scar diameter greater than approximately 5 mm without prior approval by the Sponsor based on Screening Visit images.
  • No portion of the scar is within the approximate 3.5 mm of the optical center of the cornea based on Screening Visit images.
  • Any active ocular infection in the opinion of the investigator (bacterial, viral, fungal, or protozoal) at the Screening or Day 1 Visits. Subjects with an active bacterial infection at the Screening or Day 1 Visit in the opinion of the investigator may be rescheduled to reassess the status of the infection and continue in the study if infection is deemed not active.
  • Ocular surgery planned during the study treatment period.
  • Presence or history of any ocular or systemic disorder, condition or procedure that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct.

Note: Other inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    CSB-001 QID

    One drop CSB-001 four times daily for 14 days in the study eye

    Biological: CSB-001 Ophthalmic Solution 0.1%

  • Experimental
    CSB-001 TID

    One drop CSB-001 three times daily for 14 days in the study eye

    Biological: CSB-001 Ophthalmic Solution 0.1%

Interventions

  • BiologicalCSB-001Studies of CSB-001CSB-001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

06

What researchers measure

Primary outcomes

  1. Safety as Assessed by Adverse Event Reporting

    Incidence of ocular and systemic adverse events

    Time frame: Day 1 through Day 56

  2. Safety as Assessed by Slit-lamp Biomicroscopy

    Change from baseline in staining using NEI scale (0 = absent to 3 = severe for 5 areas of the cornea) with Grade 0 (no staining) to maximum of Grade 15

    Time frame: Screening through Day 56

  3. Safety as Assessed by Best-Corrected Distance Visual Acuity

    Change from baseline using the Early Treatment Diabetic Retinopathy Study (EDTRS) visual acuity chart

    Time frame: Screening through Day 56

Secondary outcomes

  1. Efficacy as Assessed by Area of Corneal Scar

    Area of corneal scar as measured by slit lamp and anterior segment optical coherence tomography (AS-OCT) imaging

    Time frame: Screening through Day 56

  2. Efficacy as Assessed by Maximum Depth of Cornea Scar

    Depth measured with AS-OCT imaging

    Time frame: Screening through Day 56

  3. Efficacy as Assessed by Volume of Scar

    Volume measured with AS-OCT imaging

    Time frame: Screening through Day 56

  4. Efficacy as Assessed by Density of Scar

    Density based on AS-OCT and Pentacam imaging

    Time frame: Screening through Day 56

  5. Efficacy as Assessed by Contrast Sensitivity

    Contrast sensitivity measured using Pelli-Robson chart

    Time frame: Screening through Day 56

  6. Efficacy as Assessed by Distance Visual Acuity

    Visual acuity measured using the EDTRS visual acuity chart

    Time frame: Screening through Day 56

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 13, 2024
StartActual
Feb 5, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06257355
Lead sponsor
Claris Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Feb 5, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Central Operations Representative
Contact
clinicaltrials@clarisbio.com
949-354-1299

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CSB-001

Start the discussion